The Rise of Compounding: Why Section 503A Should Be Strengthened
The popularity of glucagon-like peptide-1 receptor agonists (GLP-1 drugs) such as Ozempic and Wegovy has transformed the market for weight-loss medications in the United States. Originally developed to treat type 2 diabetes, these drugs are now widely prescribed for weight management. However, demand has created nationwide shortages, prompting compounding pharmacies to produce customized versions of GLP-1 medications intended to replicate FDA-approved medications. In practice, however, this has enabled the rapid expansion of compounded GLP-1 drugs that mimic highly popular brand-name medications. Evidence of contamination, dosing errors, and serious adverse events linked to these products suggests that the current regulatory framework does not sufficiently protect consumers. Given these risks, Section 503A should be strengthened to prohibit pharmacies from producing copies of commercially available GLP-1 drugs altogether, even during shortages.